← Browse by Condition
Medical Condition

generalized myasthenia gravis

Total Trials
4
Recruiting Now
4
Trial Phases
Phase 2, Phase 3, Phase 3

ClinicalMetric tracks all active clinical trials for generalized myasthenia gravis sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — generalized myasthenia gravis Clinical Trials

How many clinical trials are currently recruiting for generalized myasthenia gravis?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for generalized myasthenia gravis, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for generalized myasthenia gravis?
generalized myasthenia gravis research spans Phase 2 (1 trial), Phase 3 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a generalized myasthenia gravis clinical trial?
Eligibility criteria for generalized myasthenia gravis trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
1
Phase 3
2
Top Sponsors
Alexion Pharmaceuticals, Inc. 1 trial
University of Missouri-Columbia 1 trial
argenx 1 trial
Vor Biopharma 1 trial

Recruiting Clinical Trials

NCT06967480
Recruiting

Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis

Enrollment
40 pts
Location
Italy
Sponsor
Alexion Pharmaceuticals, Inc.
View Trial →
NCT06064695
Recruiting

Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Myasthenia Gravis

Enrollment
16 pts
Location
United States
Sponsor
University of Missouri-Columbi...
View Trial →
NCT06392386 Phase 2, Phase 3
Recruiting

A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis

Enrollment
12 pts
Location
United States, Austr...
Sponsor
argenx
View Trial →
NCT06456580 Phase 3
Recruiting

A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)

Enrollment
180 pts
Location
United States, Argen...
Sponsor
Vor Biopharma
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology